secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-046149
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics Q1 net loss $46.8M; cash $836.9M; aleniglipron Ph2b data expected by year-end
--------------------------------------------------------------------------------

- Net loss of $46.8M in Q1 2025 vs $26.0M in Q1 2024; R&D expenses $42.9M (up from $20.7M).
- Cash, equivalents and short-term investments $836.9M as of March 31, 2025; funding through at least 2027.
- Phase 2b ACCESS and ACCESS II fully enrolled; topline 36-week data for aleniglipron expected by year-end 2025.
- Initiation of Phase 1 study for oral amylin agonist ACCG-2671 planned by year-end 2025; new preclinical data at ADA June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/0001104659-25-046149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer